Atlas Trials

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Clinical trial NCT03734991 · COMPLETED

Trial details

NCT number
NCT03734991
Sponsor
Scynexis, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Candida Vulvovaginitis
Start date
2019-01-04
Primary completion
2019-08-21
Enrollment
376

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.